Deal Highlights:

• Edelweiss successfully closed the 1st capital market transaction for Orchid Pharma post its take over by Dhanuka Group
• The OFS received an overwhelming response across all categories of Investors, a testimony to Dhanuka Lab’s ability to successfully turnaround Orchid’s business
  • Non-Retail Investors – ~2.8x; Retail – ~3.5x; Overall – ~2.9x
• Deal was strategically launched at an attractive Floor Price leading to optimum price realization in both, Non-Retail category and Retail category at ~20% and ~30% premium respectively

Our Contribution:

• We hand-held the Promoters throughout the process including in company positioning, valuation benchmarking and explaining the potential of Orchid Pharma to investors
• Enabled Deal Closure in Record Timeline – ~25 days from kick-off to deal launch
• Garnered interest from large anchor investors giving confidence to launch the trade and ensured participation from diverse investors

* By Edelweiss Securities Limited